Limits...
An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.

Heuser C, Ganser M, Hombach A, Brand H, Denton G, Hanisch FG, Abken H - Br. J. Cancer (2003)

Bottom Line: MUC1 mucin is aberrantly glycosylated and overexpressed in a number of epithelial malignancies and is therefore a promising tumour-associated antigen for target-directed immunotherapy of a panel of malignant diseases.To activate lymphocytes and natural killer (NK) cells, we here generated an anti-MUC1-scFv-IL2 fusion protein (C595scFv-Fc-IL2) that contains the C595 single-chain antibody for MUC1 binding, the human IgG1 CH2CH3 domain for protein dimerisation, and interleukin-2 (IL2) for activation of immunological effector cells.Bound to MUC1, the C595scFv-Fc-IL2 fusion protein stimulates proliferation of human activated lymphocytes in vitro.

View Article: PubMed Central - PubMed

Affiliation: Lab. Tumorgenetik, Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Joseph-Stelzmann-Str. 9, D-50931 Köln, Germany.

ABSTRACT
MUC1 mucin is aberrantly glycosylated and overexpressed in a number of epithelial malignancies and is therefore a promising tumour-associated antigen for target-directed immunotherapy of a panel of malignant diseases. In MUC1-positive tumours, MHC class I expression is frequently downregulated and MUC1-specific cytotoxic T cells (CTLs) are either not available or in a state of anergy allowing tumour growth without limitation by CTL control. To activate lymphocytes and natural killer (NK) cells, we here generated an anti-MUC1-scFv-IL2 fusion protein (C595scFv-Fc-IL2) that contains the C595 single-chain antibody for MUC1 binding, the human IgG1 CH2CH3 domain for protein dimerisation, and interleukin-2 (IL2) for activation of immunological effector cells. The fusion protein binds to MUC1-derived peptides and to MUC1-positive tumour cells with the same specificity as does the C595 monoclonal antibody. Bound to MUC1, the C595scFv-Fc-IL2 fusion protein stimulates proliferation of human activated lymphocytes in vitro. Upon binding to MUC1-positive MCF7 breast carcinoma cells, moreover, the fusion protein activates resting NK cells to tumour cell lysis. These properties make the C595scFv-Fc-IL2 fusion protein a suitable candidate for the immunotherapy of MUC1-positive tumours.

Show MeSH

Related in: MedlinePlus

Antigen binding profile of the recombinant fusion proteins C595scFv-Fc and C595scFv-Fc-IL2. Microtitre plates were coated with a set of MUC1-related (glyco-) peptides (10 μg ml−1) corresponding to mono- and oligorepeats and containing the RPAP motif (see Table 1), partially deglycosylated MUC1 antigen (100 μg ml−1), and, as control, BSM (100 μg ml−1), an anti-human IgG antibody (1 μg ml−1) and an anti-mouse IgG antibody (1 μg ml−1), respectively. The coated wells were incubated with cell culture supernatants containing the fusion proteins C595scFv-Fc (A) and C595scFv-Fc-IL2 (B), respectively, and as control with the mAb C595 (C) and a mouse IgG1 control antibody (D) (both 0.25 μg ml−1). Bound fusion proteins and antibodies were detected by a biotin-labelled anti-human IgG mAb (A and B) or a biotin labelled anti-mouse IgG mAb (C and D). The assay was performed in triplicate; data are presented as the mean±s.e.m.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376954&req=5

fig4: Antigen binding profile of the recombinant fusion proteins C595scFv-Fc and C595scFv-Fc-IL2. Microtitre plates were coated with a set of MUC1-related (glyco-) peptides (10 μg ml−1) corresponding to mono- and oligorepeats and containing the RPAP motif (see Table 1), partially deglycosylated MUC1 antigen (100 μg ml−1), and, as control, BSM (100 μg ml−1), an anti-human IgG antibody (1 μg ml−1) and an anti-mouse IgG antibody (1 μg ml−1), respectively. The coated wells were incubated with cell culture supernatants containing the fusion proteins C595scFv-Fc (A) and C595scFv-Fc-IL2 (B), respectively, and as control with the mAb C595 (C) and a mouse IgG1 control antibody (D) (both 0.25 μg ml−1). Bound fusion proteins and antibodies were detected by a biotin-labelled anti-human IgG mAb (A and B) or a biotin labelled anti-mouse IgG mAb (C and D). The assay was performed in triplicate; data are presented as the mean±s.e.m.

Mentions: The fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 and the mAb C595 were tested by ELISA for binding to partially deglycosylated MUC1 antigen from human milk fat membranes as well as to a set of MUC1 glycopeptides corresponding to parts of the repeat domain and containing the RPAP motif (Table 1). As shown in Figure 4Figure 4


An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.

Heuser C, Ganser M, Hombach A, Brand H, Denton G, Hanisch FG, Abken H - Br. J. Cancer (2003)

Antigen binding profile of the recombinant fusion proteins C595scFv-Fc and C595scFv-Fc-IL2. Microtitre plates were coated with a set of MUC1-related (glyco-) peptides (10 μg ml−1) corresponding to mono- and oligorepeats and containing the RPAP motif (see Table 1), partially deglycosylated MUC1 antigen (100 μg ml−1), and, as control, BSM (100 μg ml−1), an anti-human IgG antibody (1 μg ml−1) and an anti-mouse IgG antibody (1 μg ml−1), respectively. The coated wells were incubated with cell culture supernatants containing the fusion proteins C595scFv-Fc (A) and C595scFv-Fc-IL2 (B), respectively, and as control with the mAb C595 (C) and a mouse IgG1 control antibody (D) (both 0.25 μg ml−1). Bound fusion proteins and antibodies were detected by a biotin-labelled anti-human IgG mAb (A and B) or a biotin labelled anti-mouse IgG mAb (C and D). The assay was performed in triplicate; data are presented as the mean±s.e.m.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376954&req=5

fig4: Antigen binding profile of the recombinant fusion proteins C595scFv-Fc and C595scFv-Fc-IL2. Microtitre plates were coated with a set of MUC1-related (glyco-) peptides (10 μg ml−1) corresponding to mono- and oligorepeats and containing the RPAP motif (see Table 1), partially deglycosylated MUC1 antigen (100 μg ml−1), and, as control, BSM (100 μg ml−1), an anti-human IgG antibody (1 μg ml−1) and an anti-mouse IgG antibody (1 μg ml−1), respectively. The coated wells were incubated with cell culture supernatants containing the fusion proteins C595scFv-Fc (A) and C595scFv-Fc-IL2 (B), respectively, and as control with the mAb C595 (C) and a mouse IgG1 control antibody (D) (both 0.25 μg ml−1). Bound fusion proteins and antibodies were detected by a biotin-labelled anti-human IgG mAb (A and B) or a biotin labelled anti-mouse IgG mAb (C and D). The assay was performed in triplicate; data are presented as the mean±s.e.m.
Mentions: The fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 and the mAb C595 were tested by ELISA for binding to partially deglycosylated MUC1 antigen from human milk fat membranes as well as to a set of MUC1 glycopeptides corresponding to parts of the repeat domain and containing the RPAP motif (Table 1). As shown in Figure 4Figure 4

Bottom Line: MUC1 mucin is aberrantly glycosylated and overexpressed in a number of epithelial malignancies and is therefore a promising tumour-associated antigen for target-directed immunotherapy of a panel of malignant diseases.To activate lymphocytes and natural killer (NK) cells, we here generated an anti-MUC1-scFv-IL2 fusion protein (C595scFv-Fc-IL2) that contains the C595 single-chain antibody for MUC1 binding, the human IgG1 CH2CH3 domain for protein dimerisation, and interleukin-2 (IL2) for activation of immunological effector cells.Bound to MUC1, the C595scFv-Fc-IL2 fusion protein stimulates proliferation of human activated lymphocytes in vitro.

View Article: PubMed Central - PubMed

Affiliation: Lab. Tumorgenetik, Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Joseph-Stelzmann-Str. 9, D-50931 Köln, Germany.

ABSTRACT
MUC1 mucin is aberrantly glycosylated and overexpressed in a number of epithelial malignancies and is therefore a promising tumour-associated antigen for target-directed immunotherapy of a panel of malignant diseases. In MUC1-positive tumours, MHC class I expression is frequently downregulated and MUC1-specific cytotoxic T cells (CTLs) are either not available or in a state of anergy allowing tumour growth without limitation by CTL control. To activate lymphocytes and natural killer (NK) cells, we here generated an anti-MUC1-scFv-IL2 fusion protein (C595scFv-Fc-IL2) that contains the C595 single-chain antibody for MUC1 binding, the human IgG1 CH2CH3 domain for protein dimerisation, and interleukin-2 (IL2) for activation of immunological effector cells. The fusion protein binds to MUC1-derived peptides and to MUC1-positive tumour cells with the same specificity as does the C595 monoclonal antibody. Bound to MUC1, the C595scFv-Fc-IL2 fusion protein stimulates proliferation of human activated lymphocytes in vitro. Upon binding to MUC1-positive MCF7 breast carcinoma cells, moreover, the fusion protein activates resting NK cells to tumour cell lysis. These properties make the C595scFv-Fc-IL2 fusion protein a suitable candidate for the immunotherapy of MUC1-positive tumours.

Show MeSH
Related in: MedlinePlus